Clodronate liposomes are composed of chlorophosphate salts encapsulated within phospholipid bilayer liposomes, which are selectively ingested by macrophages following systemic administration. Within macrophage lysosomes, phosphatases gradually release the chlorophosphate salts from the liposomal vesicles, leading to their intracellular accumulation. Once a threshold concentration is reached, the accumulation results in irreversible damage to the macrophages and induces apoptosis, making clodronate liposomes a useful research tool for investigating macrophage depletion and immune modulation.

Methods for Macrophage Depletion by Clodronate liposomes in Different Tissues (For reference only; specific experimental protocols should be determined and optimized based on literature):
1. Depletion of splenic/red pulp macrophages:
Single dose: 200 μL/mouse (intravenous or intraperitoneal injection).
Long-term administration: Initial dose of 200 μL/mouse, followed by 200 μL/mouse every 2-3 days.
2. Depletion of liver/Kupffer cells:
Single dose: 200 µL/mouse (intravenous or intraperitoneal injection).
Long-term administration: Initial dose of 200 µL/mouse, followed by 200 µL/mouse every 2-3 days.
3. Depletion of alveolar macrophages:
Optimal effect achieved by intravenous injection (150-200 μL) combined with intratracheal or intranasal administration (50 μL).
4. Depletion of brain/microglia:
Intracerebroventricular or cerebrospinal fluid injection: 10 μL for mice, 50 μL for rats.